gMG Connect
  • Saved

1mo
A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval. - PubMed

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42268209

Lenacapavir-based treatments effectively suppress HIV in patients with advanced resistance, showing minimal emergent resistance.


Lenacapavir-based regimens show high virological suppression in treatment-experienced HIV patients, with low emergent resistance.

  • Saved

1mo
Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. - PubMed

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42322065

Efgartigimod and lymphoplasmapheresis show similar preoperative efficacy in myasthenia gravis, relevant for surgical specialists.


Preoperative efgartigimod and lymphoplasmapheresis show similar efficacy and safety to oral immunosuppressants in generalized myasthenia gravis, with no significant postoperative differences.

  • Saved

1mo
Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives. - PubMed

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42358938

Efgartigimod improves MG-ADL scores in generalized myasthenia gravis, showing efficacy in diverse patient populations with a favorable safety profile.


Efgartigimod improves MG-ADL scores in generalized myasthenia gravis with a favorable safety profile, including in antibody-negative and thymoma-associated MG patients.

  • Saved

2mo
Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China. - PubMed

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42254010

Explore how Chinese patients with generalized myasthenia gravis prioritize treatment safety, convenience, and rapid onset, emphasizing low adverse drug reaction risks and infrequent dosing.


Chinese gMG patients prefer safety, convenience, affordability, and rapid onset in treatments, prioritizing low ADR risk and infrequent dosing.

  • Saved

2mo
Background Image DesktopBackground Image Mobile

New evidence highlights the growing role of autoantibodies, circulating microRNAs, and immune biomarkers in improving myasthenia gravis diagnosis and disease monitoring. These emerging tools may help differentiate disease subtypes, assess treatment response, and support more personalized care strategies.

Explore evolving gMG biomarkers

  • 2mo
    1st I wasn't aware of transient neonatal MS, that is new to me and very interesting to know the signs to look for in an infant but I guess that's Show More
  • 2mo
    Very helpful to monitor treatment response.

Show More Comments